



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(MBHB Case No. 02-742-N; 400/141)**

<b>In the Application of:</b>	)	
	)	
<b>McSwiggen et al.</b>	)	
	)	<b>Examiner: ASHEN, Jon Benjamin</b>
<b>Serial No.: 10/758,155</b>	)	
	)	<b>Group Art Unit: 1635</b>
<b>Filing Date: January 12, 2004</b>	)	
	)	<b>Confirmation No. 5758</b>
<b>For: RNA Interference of Mediated Inhibition</b>	)	
<b>Of Vascular Growth Factor and Vascular</b>	)	
<b>Endothelial Growth Factor Receptor Gene</b>	)	
<b>Expression Using Short Interfering</b>	)	
<b>Nucleic Acid (siNA)</b>	)	

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 35 C.F.R. Section 1.56 and 37 C.F.R. Section 1.97 - 1.98, the Applicant wishes to make the following references of record in the above-identified application. This application is a continuation-in-part of U.S. Serial No. 10/665,951 filed September 18, 2003, and is relied upon for an earlier filing date under 35 U.S.C. Section 120. In accordance with Rule 37 CFR §1.98(d), additional references are enclosed herein. All references cited are also listed in the PTO-1449 form enclosed herewith.


In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants enclose the fee of \$180.00 pursuant to 37 C.F.R. 1.17(p) for this filing. The Commissioner is hereby authorized to charge or credit Deposit Account Number 13-2490 for any under- or over-payment of fees associated with the papers transmitted herewith, or to credit any overpayment of same.

Respectfully submitted,  
**McDonnell Boehnen Hulbert & Berghoff LLP**

Date: August 7, 2006

By:

  
Anita J. Terpstra  
Reg. No. 47,132


**McDonnell Boehnen Hulbert & Berghoff LLP**

300 South Wacker Drive, 32<sup>nd</sup> Floor

Chicago, IL 60606

Telephone: 312-913-0001

Facsimile: 312-913-0002

<b>FORM PTO-1449</b> (Rev. 2-32) <div style="text-align: center;">  </div>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>  02-742-N (400/142)	<b>Serial No.</b>  10/758,155		
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b>  McSwiggen et al.  <table border="1" style="width: 100%;"> <tr> <td data-bbox="1023 504 1315 632"> <b>Filing Date:</b>             January 12, 2004         </td> <td data-bbox="1315 504 1568 632"> <b>Group:</b> </td> </tr> </table>		<b>Filing Date:</b>  January 12, 2004	<b>Group:</b>
<b>Filing Date:</b>  January 12, 2004	<b>Group:</b>				

### FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	1.	02/094185 (PCT/US02/15876)	11/28/02	WO (Beigelman et al.)				
	2.	02/096927 (PCT/US02/17674)	12/05/02	WO (Pavco et al.)				
	3.	03/47518	06/12/03	WO (Wang et al.)				
	4.	03/070910 (PCT/US03/05022)	08/28/03	WO (Beigelman et al.)				
	5.	03/074654 (PCT/US03/05028)	09/12/03	WO (McSwiggen et al.)				

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

6.	Genbank Accession No. AF020393 (11/02/97)
7.	Genbank Accession No. AF022375 (10/07/98)
8.	Genbank Accession No. AF024710 (05/17/99)
9.	Genbank Accession No. AF035121 (12/02/97)
10.	Genbank Accession No. AF063657 (12/06/04)
11.	Genbank Accession No. AF063658 (05/16/98)

EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

**FORM PTO-1449**  
**(Rev. 2-32)**

**U.S. Department of Commerce**  
**Patent and Trademark Office**

**Atty. Docket No.**

02-742-N  
(400/142)

**Serial No.**

10/758,155

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**

McSwiggen et al.

**Filing Date:**

January 12, 2004

**Group:**

12.	Genbank Accession No. AF092125 (01/07/2000)
13.	Genbank Accession No. AF092126 (01/07/2000)
14.	Genbank Accession No. AF092127(01/07/2000)
15.	Genbank Accession No. AF095785 (05/29/2002)
16.	Genbank Accession No. AF098331 (02/08/99)
17.	Genbank Accession No. AF437895 (11/05/2001)
18.	Genbank Accession No. AF468110 (02/20/2002)
19.	Genbank Accession No. AF486837(04/03/2002)
20.	Genbank Accession No. AH006909 (10/07/99)
21.	Genbank Accession No. AJ000185 (04/15/2005)
22.	Genbank Accession No. AJ010438 (01/15/99)
23.	Genbank Accession No. AY047581 (09/03/2001)
24.	Genbank Accession No. D89630 (02/07/99)
25.	Genbank Accession No. E13256 (11/05/2005)
26.	Genbank Accession No. E13332 (11/05/2005)
27.	Genbank Accession No. E14000 (11/05/2005)
28.	Genbank Accession No. E14233 (11/05/2005)
29.	Genbank Accession No. E15156 (11/05/2005)
30.	Genbank Accession No. E15157 (11/05/2005)

**EXAMINER**

**DATE CONSIDERED**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>  02-742-N (400/142)	<b>Serial No.</b>  10/758,155
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b>  McSwiggen et al.	
		<b>Filing Date:</b>  January 12, 2004	<b>Group:</b>

	31.	Genbank Accession No. NM_002019 (04/09/2006)
	32.	Genbank Accession No. NM_002020 (06/12/2006)
	33.	Genbank Accession No. NM_002253 (06/18/2006)
	34.	Genbank Accession No. NM_003376 (06/25/2006)
	35.	Genbank Accession No. NM_003377 (03/04/2006)
	36.	Genbank Accession No. NM_004469 (04/16/2006)
	37.	Genbank Accession No. NM_005429 (06/12/2006)
	38.	Genbank Accession No. U01134 (02/02/94)
	39.	Genbank Accession No. X62568 (07/30/96)
	40.	Genbank Accession No. X94216 (04/18/2005)
	41.	Genbank Accession No. Y08736 (10/27/97)
	42.	Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found" <u>Molecular Biology</u> , 286: 5441, p.886 (1999)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>  02-742-N (400/142)	<b>Serial No.</b>  10/758,155
<b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>		<b>Applicant:</b>  McSwiggen et al.	
(Use several sheets if necessary)		<b>Filing Date:</b>  January 12, 2004	<b>Group:</b>

	*	Lin et al., "A Novel mRNA-cRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <i>Biochemical and Biophysical Research Communications</i> , 281, 639-644 (2001)
	*	Lin et al., "Policing Rogue Genes", <i>Nature</i> 402:128-129 (1999)
	*	Liszewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:8000-8004 (1993)
	*	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <i>J. Biol. Chem.</i> 270(42):24864-24870 (1995)
	*	Loakes, "The Applications of Universal DNA Base Analogues," <i>Nucleic Acids Research</i> 29:2437-2447 (2001)
	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <i>Nucleic Acids Research</i> 21:2585-2589 (1993)
	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," <i>Biochemistry</i> 32:1751-1758 (1993)
	*	Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <i>Cell</i> 110:563-574 (2002)
	*	Maurer et al., "Lipid-based systems for the intracellular delivery of genetic drugs," <i>Molecular Membrane Biology</i> 16:129-140 (1999)
	*	McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" <i>Nucleosides &amp; Nucleotides</i> 10:287-290 (1991)
	*	McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," <i>Proc. Natl. Acad. Sci. USA</i> 83:399-403 (1986)
	*	McLaren et al., "Vascular Endothelial Growth Factor (VEGF) Concentrations are Elevated in Peritoneal Fluid of Women with Endometriosis," <i>Human Reproduction</i> 11:220-223 (1996)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

02-742-N  
(400/142)

Serial No.

10/758,155

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**

McSwiggen et al.

**Filing Date:**

January 12, 2004

**Group:**

*	Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun' Type Ribozyme-trimming Plasmid," <i>Nucleic Acids Symp. Ser.</i> 27:15-16 (1992)
*	Ohno-Matsui, et al., "Inducible Expression of Vascular Endothelial Growth Factor in Adult Mice Causes Severe Proliferative Retinopathy and Retinal Detachment," <i>Animal Models</i> from the Departments of Ophthalmology and Neuroscience and Molecular Biology and Genetics, <i>Am. J. Pathology</i> , 160, 711-719 (2002)
*	Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," <i>Proc. Natl. Acad. Sci. USA</i> 89:10802-10806 (1992)
*	Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," <i>Biochimica et Biophysica Acta</i> 1238:86-90 (1995)
*	Ono et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," <i>Biochemistry</i> 30:9914-9921 (1991)
*	O'Reilly et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <i>Cell</i> 79:315-328 (1994)
*	Orgis et al., "DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression," <i>AAPS PharmSci.</i> , 3 (3) article 21 ( <a href="http://www.pharmsci.org">http://www.pharmsci.org</a> ) p. 1- 11 (2001)
*	Ormerod et al., "Effects of Altering the Eicosanoid Precursor Pool on Neovascularization and Inflammation in the Alkali-burned Rabbit Cornea," <i>American Journal of Pathology</i> 137:1243-1252 (1990)
*	Pal-Bhadra et al., "Heterochromatic Silencing and HP1 Localization in <i>Drosophila</i> Are Dependent on the RNAi Machinery," <i>Science</i> , 303, 669-672 (2004)
*	Pandey et al., "Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF- $\alpha$ -Induced Angiogenesis," <i>Science</i> 268:567-569 (1995)
*	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo," <i>Proc. Natl. Acad. Sci. USA</i> 92:5592-5596 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

**FORM PTO-1449**  
(Rev. 2-32)

**U.S. Department of Commerce**  
**Patent and Trademark Office**

**Atty. Docket No.**

02-742-N  
(400/142)

**Serial No.**

10/758,155

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**

McSwiggen et al.

**Filing Date:**

January 12, 2004

**Group:**

*	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an Escherichia coli Formylmethionine tRNA," J. Am. Chem. Soc. 109:7845-7854 (1987)
*	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," Nucleic Acids Symposium Series 31:163-164 (1994)
*	Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," Nucleic Acids Research 21:3249-3255 (1993)
*	Verdel et al., "RNAi-Mediated Targeting of Heterochromatin by the RITS Complex, Science, 303, 672-676 (2004)
*	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," Annu. Rev. Biochem. 67:99-134 (1998)
*	Volpe et al., "Regulation of Heterochromatic Silencing and Histone H3 Lysine-9 Methylation by RNAi," Science 297:1833-1837 (2002)
*	Waterhouse, et al. "Virus Resistance and gene Silencing in Plants Can Be Induced by Simultaneous Expression of Sense and Antisense RNA" Proc. Natl. Acad. Sci. USA 99:13959-13964 (1998)
*	Weckbecker et al., "Intradermal angiogenesis in nude mice induced by human tumor cells or b-FGF," Angiogenesis Key Principles—Science—Technology—Medicine pp296-301 (1992)
*	Weerasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4+ Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," Journal of Virology 65:5531-5534 (1994)
*	Wellstein and Czubayko, "Inhibition of Fibroblast Growth Factors," Breast Cancer Research and Treatment 38:109-119 (1996)
*	Wianny and Zernicka-Goetz et al., "Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development," Nature Cell Biology 2:70-75 (2000)

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.